Humana's 2027 Star Ratings turnaround and CenterWell recapitalization secure its 2028 earnings recovery, but cash windfalls remain deferred. Trading at 24.4 times 2027 transition EPS, the shares fully discount operational normalization. We reiterate our Hold rating and $440.00 target.
Key points
- $420.38 prices in a smooth Medicare Advantage recovery through 2028, discounting an earnings rebound to $33.60 per share within two years.
- $1.6 billion in CenterWell put liabilities is eliminated under the BlackRock transaction, removing parent balance sheet overhang without altering near-term underwriting cash flows.
- 12.5 times projected 2028 adjusted earnings of $35.05 per share yields an unchanged $440.00 twelve-month target, offering 4.7% upside.
The call
Humana's current price requires an immediate, frictionless return to peak profitability. The shares trade at 24.4 times our 2027 transition estimate of $17.20 per share. The market assumes disciplined bid pricing will expand individual Medicare Advantage margins without member friction, while fully absorbing 600,000 planned county plan exits next year.
Humana diluted and adjusted EPS trajectory ($)- Reported EPS
- Analyst EPS forecast
Source: Humana SEC filings and analyst forecasts as of October 2026.
We believe the 2027 Star Ratings recovery and CenterWell recapitalization derisk the long-term balance sheet, but cash flows remain depressed through 2027. Quality bonus payments for 4-star contracts do not flow until payment year 2028. Medical cost trends running between 7% and 8% keep 2027 margins constrained. The stock tracks the wider market.
Bridge from current share price to target price ($)Source: Analyst valuation bridge as of October 2026.
Valuation
| Valuation step | Value |
|---|
| FY28E Individual Medicare Advantage revenue ($B) | $115.0 |
| Individual MA pretax margin target (%) | 3.0% |
| FY28E consolidated pretax earnings ($B) | $5.6 |
| FY28E adjusted diluted EPS ($) | $35.05 |
| Target forward P/E multiple (x) | 12.5 |
| 12-month price target ($) | $440.00 |
A 12.5 times multiple reflects policy risk, Star cut-point volatility, and the one-time nature of recent Star rating gains. The resulting $440.00 target offers 4.7% upside, supporting our Hold rating.
Risks
- Elevated inpatient utilization or pharmacy inflation driving the Insurance benefit ratio above 92.5% in 2027.
- Elevated attrition among the 600,000 members affected by planned county exits, visible in monthly CMS contract enrollment.
- Derivative liabilities from minimum-return guarantees under the restructured CenterWell venture, visible in fourth-quarter disclosures.
What would change my mind
A drop in the consolidated benefit ratio below 88% during early 2027 would accelerate margin normalization and warrant an upgrade.
